Riskpilot← Back to searchSign inGet full accessCORVUS AS
ASActiveOrg 920631983Vestlia 1, 1592 Våler I ØstfoldRetail sale of pharmaceutical products · NACE 4773Est. 20183 employees
Revenue 2024
NOK 12,7M
+25% vs 2023
EBITDA margin
4.8%
+157% vs 2023
Equity ratio
28.8%
Financial strength
Net profit 2024
NOK 470K
+225% vs 2023
| Revenue | NOK 12,7M | +25% |
| EBITDA | NOK 606K | +157% |
| Net profit | NOK 470K | +225% |
| Total assets | NOK 3,4M | -17% |
| Equity | NOK 967K | -19% |
| Employees | 3 | — |
Legal name
CORVUS AS
Org number
920631983
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
20. mars 2018
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Apotekdrift og omsetning av produkter og tjenester som naturlig eller tradisjonelt hører sammen med dette.
Address
Vestlia 1, 1592 Våler I Østfold
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 990 | 8 982 | 8 297 | 10 121 | 12 700 |
| Staff expenses | −1 017 | −1 634 | −1 415 | −1 624 | −1 806 |
| EBITDA | 175 | 233 | 360 | 236 | 606 |
| Depreciation & amort. | −34 | −30 | −15 | −9 | −0 |
| EBIT | 141 | 203 | 345 | 227 | 606 |
| Net financials | −9 | −8 | −5 | −33 | −2 |
| Profit before tax | 132 | 195 | 340 | 195 | 604 |
| Tax | 29 | 43 | 75 | 50 | 133 |
| Net profit | 103 | 152 | 264 | 145 | 470 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 765 | 2 474 | 2 221 | 4 055 | 3 360 |
| Equity | 636 | 788 | 1 052 | 1 197 | 967 |
| Long-term debt | 150 | 88 | 23 | 0 | 0 |
| Short-term debt | 978 | 1 598 | 1 147 | 2 858 | 2 393 |
| Total debt | 1 129 | 1 686 | 1 169 | 2 858 | 2 393 |
EBITDA margin
4.8%
This company
15.8%
Market median
-70% vs market
20202024
Equity ratio
28.8%
This company
38.2%
Market median
-25% vs market
20202024
Return on equity
48.6%
This company
18.4%
Market median
+164% vs market
20202024
Net profit margin
3.7%
This company
8.1%
Market median
-54% vs market
20202024
Asset turnover
3.78×
This company
1.12×
Market median
+237% vs market
20202024
Debt / equity
2.47×
This company
0.62×
Market median
-298% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharmax As
CORVUS AS Board members of CORVUS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Waqar Ahmed | Chairman | 0 companies |
| Rubina Ali | Board of Directors | 0 companies |
| Akhtar Hussain | Board of Directors | 0 companies |
| Komal Khan | Board of Directors | 0 companies |